Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?

Affiliations

Free article

Editorial

B Escudier. Ann Oncol. 2011 May.

Free article

. 2011 May;22(5):995-996.

doi: 10.1093/annonc/mdq654. Epub 2011 Jan 28.

¹ Department of Medicine, Institut Gustave Roussy, Villejuif, France. Electronic address: bernard.escudier@igr.fr.

No abstract available

Comment in

Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?
Richey SL, Culp SH, Jonasch E, Matin SF, Wood CG, Tannir NM. Richey SL, et al. Ann Oncol. 2011 May;22(5):1243. doi: 10.1093/annonc/mdr132. Ann Oncol. 2011. PMID: 21521725 No abstract available.
The sequence of cytoreductive nephrectomy: glass half empty or glass half full?
Bex A, Powles T. Bex A, et al. Ann Oncol. 2011 Jul;22(7):1691; author reply 1691-2. doi: 10.1093/annonc/mdr271. Epub 2011 May 30. Ann Oncol. 2011. PMID: 21624933 No abstract available.

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Richey SL, et al. Ann Oncol. 2011 May;22(5):1048-1053. doi: 10.1093/annonc/mdq563. Epub 2010 Nov 29. Ann Oncol. 2011. PMID: 21115604 Free PMC article.
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.
Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boletti K, Sadev A, O'Brien T, Berney D, Beltran L, Haanen J, Bex A. Powles T, et al. Ann Oncol. 2011 May;22(5):1041-1047. doi: 10.1093/annonc/mdq564. Epub 2011 Jan 17. Ann Oncol. 2011. PMID: 21242586 Free PMC article. Clinical Trial.